Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S - Scandinavian Starch for Severe Sepsis/Septic Shock trial): Study protocol, design and rationale for a double-blinded, randomised clinical trial

نویسندگان

  • Anders Perner
  • Nicolai Haase
  • Jørn Wetterslev
  • Anders Åneman
  • Jyrki Tenhunen
  • Anne Berit Guttormsen
  • Gudmundur Klemenzson
  • Frank Pott
  • Karen Doris Bødker
  • Per Martin Bådstøløkken
  • Asger Bendtsen
  • Peter Søe-Jensen
  • Hamid Tousi
  • Morten Bestle
  • Malgorzata Pawlowicz
  • Robert Winding
  • Hans-Henrik Bülow
  • Claude Kancir
  • Morten Steensen
  • Jonas Nielsen
  • Bjarne Fogh
  • Kristian R Madsen
  • Nils H Larsen
  • Marcela Carlsson
  • Jørgen Wiis
  • John Asger Petersen
  • Susanne Iversen
  • Ole Schøidt
  • Siv Leivdal
  • Pawel Berezowicz
  • Ville Pettilä
  • Esko Ruokonen
  • Pål Klepstad
  • Sari Karlsson
  • Maija Kaukonen
  • Juha Rutanen
  • Sigurbergur Karason
  • Anne Lene Kjældgaard
  • Lars Broksø Holst
  • Jan Wernerman
چکیده

BACKGROUND By tradition colloid solutions have been used to obtain fast circulatory stabilisation in shock, but high molecular weight hydroxyethyl starch (HES) may cause acute kidney failure in patients with severe sepsis. Now lower molecular weight HES 130/0.4 is the preferred colloid in Scandinavian intensive care units (ICUs) and 1st choice fluid for patients with severe sepsis. However, HES 130/0.4 is largely unstudied in patients with severe sepsis. METHODS/DESIGN The 6S trial will randomize 800 patients with severe sepsis in 30 Scandinavian ICUs to masked fluid resuscitation using either 6% HES 130/0.4 in Ringer's acetate or Ringer's acetate alone. The composite endpoint of 90-day mortality or end-stage kidney failure is the primary outcome measure. The secondary outcome measures are severe bleeding or allergic reactions, organ failure, acute kidney failure, days alive without renal replacement therapy or ventilator support and 28-day and 1/2- and one-year mortality. The sample size will allow the detection of a 10% absolute difference between the two groups in the composite endpoint with a power of 80%. DISCUSSION The 6S trial will provide important safety and efficacy data on the use of HES 130/0.4 in patients with severe sepsis. The effects on mortality, dialysis-dependency, time on ventilator, bleeding and markers of resuscitation, metabolism, kidney failure, and coagulation will be assessed. TRIAL REGISTRATION ClinicalTrials.gov: NCT00962156.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Hydroxyethyl starch in severe sepsis: end of starch era?

CITATION Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, Madsen KR, Møller MH, Elkjær JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Søe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjældgaard AL, Fabritius ML, Mondrup F, Pott FC, Møller TP, Winkel P, Wetterslev J; 6S Trial Group; Scan...

متن کامل

Markers of endothelial dysfunction in patients with severe sepsis resuscitated with hydroxyethyl starch 130/0.42 vs. ringer's acetate

Introduction The Scandinavian Starch for Severe Sepsis/Septic Shock (6S) trial [1] showed increased mortality in patients with severe sepsis resuscitated with hydroxyethyl starch 130/0.42 (HES) vs. Ringer’s acetate. The underlying pathophysiological mechanisms are, however, not fully elucidated. The endothelium may be important for the effects of fluid therapy, and the different fluids may impa...

متن کامل

Effects of fluid resuscitation with synthetic colloids or crystalloids alone on shock reversal, fluid balance, and patient outcomes in patients with severe sepsis: a prospective sequential analysis.

OBJECTIVE To assess shock reversal and required fluid volumes in patients with septic shock. DESIGN Prospective before and after study comparing three different treatment periods. SETTING Fifty-bed single-center surgical intensive care unit. PATIENTS Consecutive patients with severe sepsis. INTERVENTIONS Fluid therapy directed at preset hemodynamic goals with hydroxyethyl starch (predom...

متن کامل

Patient-centered outcomes and trials of hydroxyethyl starch

Meybohm and colleagues [1] propose that hydroxyethyl starch (HES) may be used safely in hypovolemic patients by applying a clinical algorithm and by restricting the dose administered. The authors question the validity of the results of the two trials that constitute over 60% of current data [2,3] and misleadingly state that in the Crystalloid vs. Hydroxyethyl Starch Trial (CHEST), HES administr...

متن کامل

Debate on HES safety is important, but must be based on facts

The Scandinavian Starch for Severe Sepsis / Septic Shock (6S) trial showed that hydroxyethyl starch was harmful compared to Ringer's acetate in patients with severe sepsis when used according to clinical practice and in alignment with the recommendations by the manufactures and authorities. The different interpretation by Chapell and Jacob's rely on misreading of the trial publication and is no...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 12  شماره 

صفحات  -

تاریخ انتشار 2011